Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
The State of HIV/AIDS Science and Treatment Literacy in the HIV/AIDS Workforce

This survey yields some disturbing findings. Overall, the HIV science and treatment knowledge of the HIV/AIDS workforce is far too low. In many cases, people working in HIV/AIDS appear to doubt the science behind breakthrough biomedical tools for HIV prevention, and far too many members of the workforce are not familiar with many of the bio-medical interventions that will play a critical role in ending the epidemic.

Published
18 March 2015
From
Black AIDS Institute
US: A Near-Failing Science Grade for the Non-Medical HIV Workforce

On average, the survey respondents answered just 63 percent of the questions correctly, including 76 percent of those covering basic knowledge and terminology, 56 percent of the HIV treatment questions, and 46 percent of those on the use of ARVs to prevent transmission of the virus. Only 19 percent of the respondents scored 80 percent or higher on the test.

Published
18 March 2015
From
AIDSMeds
Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

Bristol-Myers Squibb took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan. That move allowed daclatasvir to carve out an early lead in Japan, but it also left investors wondering what the company's strategy for the drug in the United States would be -- particularly after the FDA balked at an initial application to approve the drug last fall. This week, Bristol-Myers shed some light on its strategy by announcing that it's resubmitting daclatasvir for approval in the U.S. as an adjunct treatment to be used alongside Gilead Sciences' (NASDAQ: GILD ) top-selling HCV drug Sovaldi in genotype 3 patients.

Published
18 March 2015
From
Motley Fool
England government unveils £650k in new HIV spending

The English Government has revealed that £800,000 of new money will be spent on HIV prevention, and to reduce the numbers of late diagnoses. A new £500,000 innovation fund was unveiled, which has been administered by Public Health England (PHE), and will allow small organisations to bid for funding of up to £50,000.

Published
13 March 2015
From
Pink News
NAT (National AIDS Trust) ‘deeply concerned’ about the impact of upheaval and delay in national HIV prevention spending

The Department of Health has announced its plans for investment in HIV prevention for 2015-16. 

Published
13 March 2015
From
NAT press release
From the Gates Foundation, Direct Investment, Not Just Grants

The Bill & Melinda Gates Foundation, which has distributed billions of dollars in grants to improve health and living conditions in developing countries, is increasingly expanding its tool kit, using some of its capital to invest directly in companies that could help advance its goals.

Published
13 March 2015
From
New York Times
Hepatitis C pills drive surge in U.S. drug costs: report

Highly effective but expensive new pills to treat hepatitis C drove a 13.1 percent increase U.S. prescription drug spending in 2014, the fastest rate of increase in more than a decade, according to Express Scripts.

Published
12 March 2015
From
Reuters
Alternative way to pay for expensive drugs may be needed, analysis says

A major challenge facing the world's health care systems is paying for a new breed of expensive breakthrough drugs. One way to address the issue is to approach it the same way as other industries where suppliers encourage investment through approaches such as equipment leases or supplier-financed credit.

Published
11 March 2015
From
Eurekalert Medicine & Health
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Sangamo's purportedly ground-breaking results in HIV with SB-728 do not stand up under close examination. SB-728 has not shown any indication that it can provide a "functional cure" for HIV, does not compare well to today's standard of care, and cannot find a partner. Sangamo refuses to conduct studies that rigorously assess whether their drugs work. This includes the inclusion of a control arm so assiduously avoided by Sangamo's management.

Published
10 March 2015
From
Seeking Alpha
Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

Based on the prescription data released by Symphony Health, the latest Bloomberg Intelligence (BI) analysis suggests that 95% of hepatitis C patients in the US are being administered with Gilead’s drugs, Harvoni and Sovaldi. On the other hand, AbbVie’s competing drug, Viekira Pak is only covering the remaining 4%.

Published
10 March 2015
From
Bidness

Filter by country